Arbutus Biopharma Files 8-K for Regulation FD Disclosure
Ticker: ABUS · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
Arbutus Biopharma filed an 8-K for a Reg FD disclosure. Details TBD.
AI Summary
Arbutus Biopharma Corp. filed an 8-K on August 5, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or other parties involved.
Why It Matters
This filing indicates Arbutus Biopharma is making a public disclosure under Regulation FD, which requires companies to share material information broadly and simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational impact detailed.
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Registrant
- Regulation FD (regulation) — Disclosure type
- August 5, 2024 (date) — Filing date
FAQ
What specific information is being disclosed under Regulation FD?
The filing does not specify the content of the Regulation FD disclosure, only that one is being made.
When was the earliest event reported in this 8-K?
The earliest event reported is August 5, 2024, which is also the date of the report.
What is Arbutus Biopharma Corp.'s principal executive office address?
The address of Arbutus Biopharma Corp.'s principal executive offices is 701 Veterans Circle, Warminster, Pennsylvania 18974.
What is the company's telephone number?
The company's telephone number is (267) 469-0914.
What is the Commission File Number for Arbutus Biopharma Corp.?
The Commission File Number for Arbutus Biopharma Corp. is 001-34949.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-08-05 16:13:03
Filing Documents
- abus-20240805.htm (8-K) — 30KB
- 0001447028-24-000066.txt ( ) — 150KB
- abus-20240805.xsd (EX-101.SCH) — 2KB
- abus-20240805_lab.xml (EX-101.LAB) — 21KB
- abus-20240805_pre.xml (EX-101.PRE) — 12KB
- abus-20240805_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 5, 2024 , Arbutus Biopharma Corporation (the "Company") and its licensee, Genevant Sciences GmbH ("Genevant"), along with Moderna, Inc. ("Moderna") and a Moderna affiliate filed a Stipulation to Extend Time (the "Stipulation") with the U.S. District Court for the District of Delaware in the lawsuit brought by the Company and Genevant against Moderna and a Moderna affiliate seeking damages for patent infringement in the manufacture and sale of MRNA-1273, Moderna's vaccine for COVID-19. The parties are requesting an amended case schedule to accommodate certain outstanding discovery from Moderna and third parties, as specified in the Stipulation, which would move the start of the trial to September 24, 2025 (subject to the Court's availability) if the Stipulation is granted. The Stipulation, and the new deadlines set forth therein, are subject to the approval of the Court.
Forward-Looking Statements and Information
Forward-Looking Statements and Information This Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this Current Report on Form 8-K include statements about the Company's lawsuit against Moderna and a Moderna affiliate. With respect to the forward-looking statements contained in this Current Report on Form 8-K, the Company has made numerous assumptions regarding the timing of the lawsuit and related discovery, pre-trial and trial matters. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: uncertainties associated with litigation generally and patent litigation specifically. A more complete discussion of the risks and uncertainties facing the Company appears in The Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 5, 2024 ARBUTUS BIOPHARMA CORPORATION By: /s/ David C. Hastings Name: David C. Hastings Title: Chief Financial Officer